It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Achilles Therapeutics prices IPO at $175m as Syncona keeps 27% stake

Wed 31 March 2021 07:41 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Syncona portfolio biopharma company Achilles Therapeutics said its US initial public offering (IPO) will raise $175.5m (£127.8mln).

Achilles, which is developing precision T cell therapies to treat solid tumours, will place 9.7m American depositary shares (ADS) on the Nasdaq exchange at $18 each. Trading is expected to start on Wednesday.

Syncona said it would retain a 27% stake in Achilles worth £145.4mln after the float, a £50.6m rise in value since it first invested.

"Today's milestone is a significant achievement for Achilles as it seeks to deliver its ambition of bringing neo-antigen targeted T-cell therapies to cancer patients," said Syncona investment management chief executive Martin Murphy.

"It comes less than five years after Syncona's first investment at the foundation of the company and we look forward to seeing the company's continued progress."

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More company news from ShareCast